anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hypertrophic scar development is a complication associated with wound healing, impacting local appearance and function. The type I/III collagen ratio affects the extent of hypertrophic scarring; a reduced ratio can ameliorate this. In this study, recombinant human collagen type III was developed. Liquid chromatography-tandem mass spectrometry was used to determine its amino acid sequence and confirm its high level of homology with natural human type III collagen. Recombinant human collagen type III displayed no cytotoxicity and did not confer skin irritation and sensitization. Immunofluorescence and western blot analyses of histidine following incubation with fibroblasts suggested cell entry of recombinant human collagen type III. Furthermore, recombinant human collagen type III promoted the synthesis of the natural type III collagen in fibroblasts, resulting in a more obvious increase of type III collagen content in fibroblasts than that of type I collagen, and then decreased the ratio of type I/III collagen. The results of 5-ethynyl-2'-deoxyuridine staining assay suggested enhanced fibroblast proliferation. Following local injection of recombinant human collagen type III, rabbit ear scarring was significantly reduced after 60 days. Vancouver Scar Scale evaluation showed that all index scores were significantly reduced. Western blotting and Picro-Sirius red staining showed that the natural type III collagen increase in scar tissue was greater than that of type I collagen, decreasing the type I/III ratio. In summary, recombinant human collagen type III can be taken up by fibroblasts and promote natural collagen synthesis-especially that of type III-thereby reducing the type I/III ratio and improving hypertrophic scarring.
The most common lung complications of severe COVID-19 are pneumonia and hypoxemic respiratory failure/ARDS. Manifestations of lung inflammation or fibrosis were also observed in late stages of COVID-19 causing respiratory sequelae. Fibrous lesions may form during the healing of pulmonary chronic inflammation or proliferative diseases, with gradual replacement of cellular components by scar tissues indicating a poor outcome of COVID-19. Ultrasound allows to stratify the severity of lung damage and combined with the clinic, can help estimate the patient's prognosis and support therapeutic decision-making. On the other hand, pulmonary inflammatory processes and fibrosis are responsible for a decrease in respiratory distensibility or pulmonary compliance. Pulmonary parenchyma distensibility is known as static distensibility or compliance and it´s calculated by mechanical ventilators during general anesthesia.

There are no studies that determine the results of lung ultrasound and pulmonary compliance in preoperative and intraoperative period respectively in postCOVID patients, and the postoperative complications of postCOVID patients are poorly understood.
The invention discloses a lycium barbarum polysaccharide with an immunoregulation function and a preparation method thereof. The polysaccharide is extracted by 80% ethanol to remove small molecular substances, protein is removed by a Sevage method, macroporous resin is decolorized, and the lycium barbarum polysaccharide is obtained by DEAE ion exchange and Sephacryls-100 gel permeation chromatography separation and purification. The polysaccharide is composed of rhamnose, arabinose, xylose, mannose, glucose and galactose. The skeleton structure of the lycium barbarum polysaccharide is determined through partial acid hydrolysis and oligosaccharide sequencing analysis, and the nuclear magnetic resonance spectrogram belongs to the side chain structure information of the lycium barbarum polysaccharide. The lycium barbarum polysaccharide prepared by the invention can enhance the proliferation activity of RAW264.7 cells, up-regulate the release of cell factors and inflammation media and the expression of mRNA (messenger ribonucleic acid), and activate MAPK (mitogen activated protein kinase) pathway to play a role in immunoregulation. The fructus Lycii polysaccharide can be used as immunologic adjuvant and functional food or medicine for enhancing immunity.
Twelve Czech national and international-level fin-swimmers participate in this trial. Participants take molecular hydrogen via drinking hydrogen-rich water (HRW) or placebo three days before (1260 ml/day) and during testing day (2520 ml). All participants participate in two testing session and receive HRW and placebo in random order. Each session includes two training units in a 25-m indoor swimming pool and a 24-hour monitored recovery. The first training unit takes place in the morning between 9 and 11 AM and includes three high intensity interval sets. The afternoon training unit includes a continuous 400-m competitive performance. The washout period between testing sessions is 7 days. The variables assessed are as follows: swimming times, heart rate variability, lower limb explosive strength, rating of perceived exertion, subjective perceived muscle soreness, creatine kinase, blood lactate, and protein carbonyls. Statistical analysis is based on analysis of variance for repeated measures with factors: water (HRW and placebo), time, and interaction. Fisher's post-hoc tests is used for pairwise comparisons. The significance level is set at 0.05.
The invention discloses a pharmaceutical composition containing adenosine or derivatives of adenosine. The pharmaceutical composition comprises a composition of adenosine or the derivatives of adenosine and clinically compounds which lead to liver injury. The derivatives of adenosine are adenosine monophosphate, adenosine diphosphate or adenosine triphosphate. The clinically compounds which lead to liver injury comprise compounds for treating tuberculosis, antipyretic, analgesic and anti-inflammatory compounds, compounds for treating mental diseases, antibacterial compounds, hormonic compounds or anti-tumor compounds. The mouse model adopted by the invention is a mouse acute liver injury model induced by the compounds which lead to liver injury. The mass ratio of adenosine or the derivatives of adenosine and the compounds in the composition is (1:9)-(9:1). The pharmaceutical composition containing adenosine or the derivatives of adenosine and the compounds can reduce activity of AST (Aspartate Amino Transferase) and ALT (Alanine Amino Transferase) in liver injury and reduce necrosis area of parenchyma cells of liver, so that liver injury caused by the compounds is alleviated. The pharmaceutical composition disclosed by the invention shows that adenosine or the derivative of adenosine has protective effect on liver injury caused by the compounds.
The invention concerns novel flavone and isoflavone derivatives of formulae (Ia) and (Ib) wherein: X represents a group of formula -COOR, or -PO(OR)¿2?; R represents a hydrogen atom or an alkaline or alkaline-earth metal, or a lower alkyl group; R¿1? represents a hydroxy group, a lower alkoxy group or an acyloxy group; R¿2? and R¿3?, identical or different, represent a hydrogen or halogen atom, or a trifluoromethyl group, a trichloromethyl group, a hydroxy group, an alkoxy group or an acyloxy group comprising 1 to 5 carbon atoms, or R¿2? and R¿3? can combine to form an alkylene dioxy group. The invention is useful for treating rheumatic diseases.
The invention belongs to the technical field of traditional Chinese medicines, and relates to an externally applied drug for treating rhinitis and a preparation method thereof. The externally applied drug is made of ten Chinese medicinal materials including fructus xanthil, musk, scorpion tail, centipede head, rhinoceros horn, flower bud of lily magnolia, asarum, Chinese honeylocust thorn, grassleaved sweetflag rhizome and dried alum. The externally applied drug is made based on hereditary secret formula of the inventor and by combining years of personal clinical experience and repeated tests, and has unique medication method; therefore, the externally applied drug has unique curative effect on stubborn rhinitis. The externally applied drug has proper and strict formula and a unique preparation method. The externally applied drug can quickly cure the symptoms caused by rhinitis such as nasal obstruction and anosmia, headache and dizziness, anorexia and nausea, insomnia and amnesia, fever and the like. The externally applied drug has unique curative effect on sinusitis, frontal sinusitis, hypertrophy of nasal conchae and nasal polyp, and has the advantages of quick effect, short treatment course, high curative rate and low expenses.
Zolpidem, N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide, is a hypnotic agent widely used in clinical practice but is detected in many clinical cases of fatal intoxication and suicide. In forensic toxicology, the precise determination of zolpidem concentration in blood is a must to provide concrete evidence of death by zolpidem poisoning. However, the concentrations of zolpidem in blood at autopsy often differ from those at the estimated time of death. In the present study, we found that zolpidem was degraded by hemoglobin (Hb) via the Fenton reaction at various temperatures. The mechanism underlying zolpidem degradation involved the oxidation of its linker moiety. The MS and MS/MS spectra obtained by liquid chromatography quadrupole-Orbitrap mass spectrometry (LC-Q-Orbitrap-MS) showed the formation of 2-hydroxy-N,N-dimethyl-2-(6-methyl-2-(p-tolyl)imidazo[1,2-a]pyridin-3-yl)acetamide (2-OH ZOL) in Hb/H2O2 solution incubated with zolpidem and in the blood of several individuals who died from ingestion of zolpidem. These results suggest that 2-OH ZOL is the post-mortem product of zolpidem degradation by Hb via the Fenton reaction.
Fully elucidating the burden that Lennox-Gastaut syndrome (LGS) places on individuals with the disease and their caregivers is critical to improving outcomes and quality of life (QoL). This systematic literature review evaluated the global burden of illness of LGS, including clinical symptom burden, care requirements, QoL, comorbidities, caregiver burden, economic burden, and treatment burden (PROSPERO ID: CRD42022317413). MEDLINE, Embase, and the Cochrane Library were searched for articles that met predetermined criteria. After screening 1442 deduplicated articles and supplementary manual searches, 113 articles were included for review. A high clinical symptom burden of LGS was identified, with high seizure frequency and nonseizure symptoms (including developmental delay and intellectual disability) leading to low QoL and substantial care requirements for individuals with LGS, with the latter including daily function assistance for mobility, eating, and toileting. Multiple comorbidities were identified, with intellectual disorders having the highest prevalence. Although based on few studies, a high caregiver burden was also identified, which was associated with physical problems (including fatigue and sleep disturbances), social isolation, poor mental health, and financial difficulties. Most economic analyses focused on the high direct costs of LGS, which arose predominantly from medically treated seizure events, inpatient costs, and medication requirements. Pharmacoresistance was common, and many individuals required polytherapy and treatment changes over time. Few studies focused on the humanistic burden. Quality concerns were noted for sample representativeness, disease and outcome measures, and reporting clarity. In summary, a high burden of LGS on individuals, caregivers, and health care systems was identified, which may be alleviated by reducing the clinical symptom burden. These findings highlight the need for a greater understanding of and better definitions for the broad spectrum of LGS symptoms and development of treatments to alleviate nonseizure symptoms.
A face-to-face motivational interview session was applied to each participant in the experimental (intervention) group by the researcher once a week in the 1st month and once in 15 days in the 2nd month. The interviews were held in 6 sessions in total, and each interview was completed in approximately 45-60 minutes.
LFMT-capsules. 3 times bulk, and further continuous administration. This arm is also treated pre- and probiotics.
The subject disclosure relates to the identification of mutations in the I i  protein which result in an alteration of the endoprotease cleavage pattern of the mutant I i  as compared with the endoprotease cleavage pattern of the wild type product. Methods for the identification of such mutants, and the mutants themselves are useful for the identification of classes of compounds to be further tested for immunomodulatory activity. A specific example of such a use is the screening of small organic compounds for the ability to bind to an intermediate in the I i  endoprotease processing pathway. An small organic molecule having the ability to bind to such an intermediate can be further screened for the ability to modulate antigen presentation. The present invention also relates to the identification of immunomodulatory peptides. Peptides which either enchance or inhibit MHC Class II-restricted presentation of antigenic peptides are identified.
INTRODUCTION: evaluation of predictors of periprosthetic fracture in loosened femoral stems.
MATERIAL AND METHODS: retrospective case-control study comparing aseptic loosened stems in two groups: cases: patients who experienced periprosthetic femoral fracture before replacement could be performed (n = 9). Controls: experienced prosthetic replacement without fracture (n = 19).
RESULTS: pain intensity (VAS) was the most important aspect (p = 0.01), predominating in the controls. The simple radiological parameters did not show statistically significant findings predictive of peri-prosthetic fracture (number of Gruen zones, sum of them in mm, stress shielding, pedestal, polyethylene wear, stem subsidence). The role of complementary tests (CT and scintigraphy) for the definitive diagnosis of loosening was relevant, but not significant. The type of implant showed no differences. Overall implant survival was higher in cases than in controls (p = 0.016). This difference continues when comparing each loosened stem until fracture or replacement (p = 0.024).
CONCLUSION: the main factor protecting against fracture is the replacement of a stem with clinical and radiological diagnosis of loosening. Adequate follow-up of the patient plays a determining role in this, especially when considering the greater intensity of pain in the controls, which used to guide surgeons to perform replacements before the fracture occurred. This is reinforced if we take into account that up to one third of the cases did not have regular check-ups, and therefore did not have the opportunity for replacement prior to the fracture. The role of complementary tests (CT and scintigraphy) is also very important, taking into account the low diagnostic yield obtained from simple X-rays.
Chronic Obstructive Pulmonary Disease (COPD) is an increasingly prevalent and costly chronic health condition, and is the third major cause of morbidity and mortality in the United States. Self-management treatment programs for COPD are shown to improve health-related quality of life and prevent COPD-related hospitalizations. Despite their clinical benefits, these programs are typically multi-component and time- and resource-intensive. To date, no study has been conducted to isolate the role of individual self-management treatment components in contributing to improved COPD outcomes. The proposed research will establish the feasibility of using the Multiphase Optimization Strategy (MOST) framework to optimize COPD self-management treatment delivered by the American Lung Association (ALA) Helpline. Treatment components to be evaluated include duration of self-management education, ground-based walking training, inhaler training, and caregiver support. The primary outcome is health-related quality of life, with secondary outcomes of COPD symptom burden, self-management behaviors, and hospitalization. Specific aims are:

Aim 1: Design a factorial experiment and develop operational procedures. The investigators will design a factorial experiment with the same number of experimental conditions and length of follow-up as the planned optimization trial. In collaboration with the ALA COPD Helpline, the investigators will develop operational procedures (i.e., recruitment, screening, randomization, and database management) for successful implementation.

Aim 2: Establish feasibility and acceptability by pilot testing the study design. The investigators will deliver treatment to three participants per experimental condition (N=48) with good fidelity, and will remotely assess baseline, mediator, and outcome variables. The investigators will conduct qualitative interviews at end-of-treatment with 15-20 participants. Resulting values will provide estimates of recruitment and retention rates, treatment fidelity, acceptability of treatment components, and outcome measure variability to inform a subsequent, fully-powered optimization trial. The primary outcome is health-related quality of life, with secondary outcomes of COPD symptom burden, self-management behaviors, and hospitalization.
The invention discloses a rheumatic medicament belonging to technical field of medicines. The background technology is as follows: rheumatism is characterized in that the vessels are blocked, and the neurologic function declines, in order to heal the rheumatism, the sediments in the vessels need to be massaged and the channels need to be dredged, and the circulation of blood need to be invigorated, the neurologic function needs to be improved, so that the pain caused by rheumatism can be healed thoroughly. Fever rheumatoid arthritis is difficult to treat, the joint is red and swell, and the arch of the foot and the palm of the hand fever, in order to treat the fever rheumatism, the wind fire in the body needs to be removed, then herbal medicines are used for wrapping the arch of the foot and the palm of the hand, and then the rheumatic medicament is taken, so that the arthritis can be healed gradually. According to the secret prescription handed down from the ancestors, the rich resources in Dehong regions of Yunnan are utilized, and through the practice confirmation of the folk treatment in more than 300 years, the pain of a patient can be relieved in a short time and the patient can get well. The formula of the rheumatic drug consists of four medicines, namely, sappanwood, red flower and Shansheng, wherein the Shansheng is not contained in the herbal medicines, but has a good effect on treating malnutrition disease. The rheumatic drug is technically characterized by consisting of four medicines, the first medicine is used for massaging blood sprays settled in the vessels; the second and the third medicines are used for dredging the channels and activating the blood; and the fourth medicine is used for improving the neurologic function. The rheumatic drug is brewed by rice wine, and the fever rheumatism needs to be treated by the herbal medicines firstly.
The study aims to summarize the clinical characteristics of patients with ectopic gastric mucosa in the small intestine, comparing clinical presentation differences between domestic and foreign patients through literature review. The clinical characteristics of cases diagnosed with ectopic gastric mucosa in the small intestine at Peking Union Medical College Hospital from January 2000 to January 2024 were retrospectively analyzed. By searching databanks, such as PubMed, EMBASE, the Cochrane Library, Wanfang, VIP, CNKI, and etc (the inclusion period was from the establishment of the database to January 1, 2024). The literature review was conducted on ectopic gastric mucosa in the small intestine. A total of 10 cases were included, all male, age [M (Q1, Q3)] was 27 (13-69) years old. Gastrointestinal bleeding was the first manifestation in most cases, with severe cases leading to hemorrhagic shock. Abdominal CT indicated local intestinal wall thickening and luminal narrowing in 3 cases. Four cases lesions were located at the beginning of the jejunum and 6 lesions were located in the end segment of ileum. All cases underwent local lesion resection, with postoperative pathology confirming ectopic gastric mucosa. Symptoms disappeared postoperatively, with a follow-up period of 0.5-3.0 years. Literature review indicates that the main clinical manifestation of gastric mucosa ectopia in the small intestine in China is gastrointestinal bleeding, while foreign patients are often complicated with intestinal duplication and intussusception, with abdominal pain and vomiting as the primary and main symptoms. The occurrence rate of intestinal obstruction in female patients, both domestically and abroad, is higher than that in male patients. The occurrence rate of ileal lesions with intestinal obstruction and small intestinal duplication is higher than that of duodenal lesions in both domestic and foreign patients. Local small intestine resection is an effective treatment method with generally good prognosis. Ectopic small intestinal mucosa is relatively rare, with symptoms of gastrointestinal bleeding and intestinal obstruction being common presentations, which can serve as one of the differential diagnoses for unexplained gastrointestinal bleeding.
The procedure can be carried out in single or two visits. Variations in root canal treatment protocols however will make it difficult to compare with pulpotomy so the aim is to standardize the protocols for the following variables including use of rubber dam, Irrigation protocol with 2-2.5% sodium hypochlorite; working length with combined radiographs and apex locators, automated instrumentation to accompany hand instrumentation and preparation to apical size 2-3 larger than the initial binding file. Canal to be medicated with non-setting calcium hydroxide if done in two visits and root canal filling with gutta percha and traditional sealers (warm or cold lateral condensation) and good coronal seal.
<P>PROBLEM TO BE SOLVED: To provide an incense stick bundle with an ignition agent, efficiently and surely ignited and uniformly igniting the front end incense stick group by devising attaching specifications of the ignition agent to be attached on the front end side of the incense stick bundle.  <P>SOLUTION: The ignition agent is attached on one end surface of the incense stick bundle to enfold the corner part near the periphery of the end surface except at least the midsection. The attaching specifications may indicate a formation that the ignition agent is continuously linked around to integrate with the incense stick front end of one side, or a formation that the ignition agent is discontinuously linked around without attaching on a part of peripheral edge part. Wherein, the ignition agent is attached after impregnating or coating an oxidant near one end side including the front end surface previously. The ignition agent may be not only set on the peripheral edge part but also further attached on the midsection of one end surface. In the case, the thickness on the midsection is made thiner than that on the peripheral edge part. When being attached on the peripheral edge part and the midsection, it is preferable to form small pores or cracks aerating to the inside or the outside of the incense stick bundle.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Motor weakness has been reported rarely in patients receiving combination antiretroviral therapy including stavudine. Most of these cases occurred in the setting of lactic acidosis. The evolution of motor weakness may mimic the clinical presentation of Guillain-Barré syndrome (including respiratory failure). Symptoms may continue or worsen following discontinuation of therapy.

Peripheral neuropathy, manifested by numbness, tingling, or pain in the hands or feet, has been reported in patients receiving stavudine therapy. Peripheral neuropathy has occurred more frequently in patients with advanced HIV disease, with a history of neuropathy, or in patients receiving other drugs that have been associated with neuropathy, including didanosine (see ADVERSE REACTIONS).